ReviewUrologie (Heidelberg, Germany)2025
[Things worth knowing about drug-based osteoprotection in uro-oncology].
Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases in uro-oncology bear a high risk for bone-related complications (skeletal-related events, SRE). The presence of SRE is associated with an increased risk for death, which is markedly increased in the presence of pathological fractures. Prostate cancer and renal cell carcinoma in particular result in bone metastases in advanced stages. The SREs also represent an economic problem and lead to nearly double the costs of treatment. Zoledronic acid and denosumab are both approved osteoprotective drugs for the prevention or delay of SRE in metastatic disease. Interestingly, zoledronic acid does not reduce the incidence of SRE in hormone-sensitive prostate cancer. The dosage and administration of both drugs differ in the treatment of bone metastases and treatment or prophylaxis of osteoporosis. Long-term treatment with one of these two drugs is associated with the risk of development of medication-related osteonecrosis of the jaw (MRONJ). Routine controls of the oral cavity before and during treatment are mandatory in these patients.
Indexed as
Identifiers
39976747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.